Moreover, we recently found that Bcr-Abl negatively regulates the expression of ZNF224 in CML cells via transcriptional repression; consistently, inhibition of Bcr-Abl tyrosine kinase activity, by Imatinib and second generation tyrosine kinase inhibitors, resulted in the up-regulation of ZNF224 expression [25]. This evidence concerns the gene ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive.